HOMOEOPATHY FOR MYELOFIBROSIS
A defect in the bone marrow of people with myelofibrosis causes the over- or underproduction of different blood cells. Myelofibrosis (MF), also known as “blood cancer,” or “bone marrow disorder,” is one of a group of illnesses known as “myeloproliferative neoplasms” (MPNs).
Myelofibrosis is a disease that affects both men and women equally and can strike at any age, but the majority of those who are diagnosed with it are between the ages of 50 and 80, accounting for approximately 16,000 to 18,500 of the disease’s sufferers in the United States.
As the disease worsens, the marrow becomes fibrosed in mylofibrosis. At first, the marrow is hypercellular in this condition, with an excess of abnormal megakaryocytes that release growth factors to the marrow microenvironment, such as platelet derived growth factor, which causes a reactive proliferation of fibroblasts.
Leucoerythroblastic anemia is characterized by circulating immature red blood cells (increased reticulocytes and nucleated red blood cells), granulocyte precursors (myelocytes), and giant platelets. The white count ranges from low to moderately high, and the platelet count may be high, normal, or low. Urate levels may be high due to increased cell b.
Each person’s experience of living with myelofibrosis (MF) is unique, but no matter how myelofibrosis affects you, it is crucial to monitor and record any symptoms. By doing so, your healthcare team can better manage and treat any symptoms you may have.
These are some possible MF symptoms:
· Abdominal pain
· Night sweats
· Bone/muscle pain
· Easy bruising or bleeding
Left-sided rib pain
· Early feeling of fullness
· Weight loss
· Shortness of breath
Blood stem cells, which can replicate and divide into the various specialized cells that make up your blood — red blood cells, white blood cells, and platelets — have the capacity to develop a genetic mutation that leads to myelofibrosis.
The genetic mutation in blood stem cells is not fully understood.
Blood production is seriously impacted as more and more of the mutated blood stem cells are produced, spreading the mutation to new cells as they divide and replicate.
Myelofibrosis is characterized by scarring of the normally spongy bone marrow, which leads to anemia and an excess of white blood cells with variable levels of platelets.
Knowing whether your myelofibrosis is associated with the Janus kinase 2 (JAK2) gene or others helps determine your prognosis and your treatment. Several specific gene mutations have been identified in people with myelofibrosis, with the Janus kinase 2 (JAK2) gene being the most prevalent.
The strength of homoeopathy is its obvious efficacy because it treats the sick person holistically by promoting inner balance at the mental, emotional, spiritual, and physical levels. Homoeopathy is a rapidly expanding system that is practiced almost everywhere in the world.
In homeopathic treatment, medicines are chosen after a thorough individualizing examination and case-analysis, which takes into account the patient’s medical history, physical and mental constitution, likes and dislikes, thermal status, etc. A miasmatic tendency (predisposition/susceptibility) is also frequently taken into account.
Important medications for myelofibrosis include arsenic iodide, natrum sulph, kali sulph, phosphorus, natrum muriaticum, ceonanthus, radium bromide, sulphur, thiosinaminum, and vanadium metal.